Hallucinogen persisting perceptual disorder: a scoping review covering frequency, risk factors, prevention, and treatment

References

• Nichols DE, Barker EL. Psychedelics. Pharmacol Rev. 2016;68(2):264–355.
   PubMed Web of Science ®Google Scholar
• Begola MJ, Schillerstrom JE. Hallucinogens and their therapeutic use: a literature review. J Psychiatr Pract. 2019;25(5):334–346.
   PubMed Web of Science ®Google Scholar
• Vollenweider FX, Preller KH. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nat Rev Neurosci. 2020;21(11):611–624.
   PubMed Web of Science ®Google Scholar
• Lerner A, Rudinski D, Bor O, et al. Flashbacks and HPPD: a Clinical-oriented Concise Review. Isr J Psychiatry Relat Sci. 2014;51:296–301.
   PubMed Web of Science ®Google Scholar
• Orsolini L, Papanti GD, De Berardis D, et al. The “Endless Trip” among the NPS users: psychopathology and psychopharmacology in the Hallucinogen-Persisting perception disorder. a systematic review. Front Psychiatry. 2017;8:240.
   PubMed Web of Science ®Google Scholar
• Baggott MJ, Coyle JR, Erowid E, et al. Abnormal visual experiences in individuals with histories of hallucinogen use: a web-based questionnaire. Drug & Alcohol Dependence. 2011;114(1):61–67.
   PubMed Web of Science ®Google Scholar
• Diagnostic and statistical manual of mental disorders. Washington, D.C.: American Psychiatric Association; 2013.
   Google Scholar
• Carhart-Harris RL, Bolstridge M, Day CMJ, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology (Berl). 2018;235(2):399–408.
   PubMed Web of Science ®Google Scholar
• Agin-Liebes GI, Malone T, Yalch MM, et al. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol. 2020;34(2):155–166.
   PubMed Web of Science ®Google Scholar
• Davis AK, Barrett FS, May DG, et al. Effects of Psilocybin-Assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2021;78(5):481.
   PubMed Web of Science ®Google Scholar
• Szigeti B, Kartner L, Blemings A, et al. .Baker CI, Shackman A, Perez Garcia-Romeu A Self-blinding citizen science to explore psychedelic microdosing. eLife.2021;10.
   PubMed Web of Science ®Google Scholar
• Johnson MW, Richards WA, Griffiths RR. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22(6):603–620.
   PubMed Web of Science ®Google Scholar
• Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19–32.
   Google Scholar
• Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467–473.
   PubMed Web of Science ®Google Scholar
• Lev-Ran S, Feingold D, Rudinski D, et al. Schizophrenia and hallucinogen persisting perception disorder: a clinical investigation. Am J Addict. 2015;24(3):197–199.
   PubMed Web of Science ®Google Scholar
• Moola S, Munn Z, Tufanaru C Chapter 7: Systematic reviews of etiology and risk. JBI Manual for Evidence Synthesis. . 2020.
   Google Scholar
• Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–605.
   PubMed Web of Science ®Google Scholar
• National heart, lung, and blood institute, Study Quality Assessment Tools. 2019.
   Google Scholar
• Levels of Evidence Working Group. The Oxford 2011 levels of evidence. Oxford, England: Oxford Centre for Evidence-Based Medicine; 2011.
   Google Scholar
• Abraham HD, Duffy FH. EEG coherence in post-LSD visual hallucinations. Psychiatry Res. 2001;107(3):151–163.
   PubMed Web of Science ®Google Scholar
• Abraham HD, Duffy FH. Stable quantitative EEG difference in post-LSD visual disorder by split-half analysis: evidence for disinhibition. Psychiatry Res. 1996;67(3):173–187.
   PubMed Web of Science ®Google Scholar
• Abraham HD, Mamen A. LSD-like panic from risperidone in post-LSD visual disorder. J Clin Psychopharmacol. 1996;16(3):238–241.
   PubMed Web of Science ®Google Scholar
• Aldurra G, Crayton JW. Improvement of hallucinogen persisting perception disorder by treatment with a combination of fluoxetine and olanzapine: case report. J Clin Psychopharmacol. 2001;21(3):343–344.
   PubMed Web of Science ®Google Scholar
• Hermle L, Simon M, Ruchsow M, et al. Hallucinogen-persisting perception disorder. Ther Adv Psychopharmacol. 2012;2(5):199–205.
   PubMedGoogle Scholar
• Kurtom M, Henning A, Espiridion ED. Hallucinogen-persisting perception disorder in a 21-year-old man. Cureus. 2019;11(2):e4077.
   PubMed Web of Science ®Google Scholar
• Lerner A, Goodman C, Rudinski D, et al. LSD Flashbacks - the appearance of new visual imagery not experienced during initial intoxication: two case reports. J Psychiatry. 2014;51:307–309.
   Google Scholar
• Lerner AG, Finkel B, Oyffe I, et al. Clonidine treatment for hallucinogen persisting perception disorder. J Psychiatry. 1998;155:1460.
   Google Scholar
• Lerner AG, Oyefe I, Isaacs G, et al. Naltrexone treatment of hallucinogen persisting perception disorder. J Psychiatry. 1997;154:437.
   Google Scholar
• Lerner AG, Gelkopf M, Oyffe I, et al. LSD-induced hallucinogen persisting perception disorder treatment with clonidine: an open pilot study. Int Clin Psychopharmacol. 2000;15(1):35–37.
   PubMed Web of Science ®Google Scholar
• Lerner AG, Skladman I, Kodesh A, et al. LSD-induced hallucinogen persisting perception disorder treated with clonazepam: two case reports. J Psychiatry. 2001;38:133–136.
   Google Scholar
• Lerner AG, Shufman E, Kodesh A, et al. LSD-induced hallucinogen persisting perception disorder with depressive features treated with reboxetine: case report. J Psychiatry. 2002;39:100–103.
   Google Scholar
• Lerner A, Lev-Ran S. LSD-associated “Alice in Wonderland Syndrome”(AIWS): a Hallucinogen Persisting Perception Disorder (HPPD) Case Report. J Psychiatry. 2015;52:67–68.
   Google Scholar
• Morehead DB. Exacerbation of hallucinogen-persisting perception disorder with risperidone. J Clin Psychopharmacol. 1997;17(4):327–328.
   PubMed Web of Science ®Google Scholar
• Subramanian N, Doran M. Improvement of hallucinogen persisting perception disorder (HPPD) with oral risperidone: case report. Ir J Psychol Med. 2014;31(1):47–49.
   PubMedGoogle Scholar
• Lev-Ran S, Feingold D, Goodman C, et al. Comparing triggers to visual disturbances among individuals with positive vs negative experiences of hallucinogen-persisting perception disorder (HPPD) following LSD use. Am J Addict. 2017;26(6):568–571.
   PubMed Web of Science ®Google Scholar
• Lerner AG, Gelkopf M, Skladman I, et al., Clonazepam treatment of lysergic acid diethylamide-induced hallucinogen persisting perception disorder with anxiety features. Int Clin Psychopharmacol. 18(2): 101–105. 2003.
   PubMed Web of Science ®Google Scholar
• Espiard M-L, Lecardeur L, Abadie P, et al. Hallucinogen persisting perception disorder after psilocybin consumption: a case study. Eur Psychiatry. 2005;20(5–6):458–460.
   PubMed Web of Science ®Google Scholar
• Ikeda A, Sekiguchi K, Fujita K, et al. 5-methoxy-N,N-diisopropyltryptamine-induced flashbacks. Am J Psychiatry. 2005;162(4):815.
   PubMed Web of Science ®Google Scholar
• Skryabin VY, Vinnikova M, Nenastieva A, et al. Hallucinogen persisting perception disorder: a literature review and three case reports. J Addict Dis. 2018;37(3–4):268–278.
   PubMed Web of Science ®Google Scholar
• Anderson L, Lake H, Walterfang M. The trip of a lifetime: hallucinogen persisting perceptual disorder. Australas Psychiatry. 2018;26(1):11–12.
   PubMed Web of Science ®Google Scholar
• Coppola M, Mondola R. JWH-122 consumption adverse effects: a case of Hallucinogen Persisting Perception Disorder Five-Year Follow-Up. J Psychoactive Drugs. 2017;49(3):262–265.
   PubMed Web of Science ®Google Scholar
• Lerner A, Goodman C, Bor O, et al. Synthetic Cannabis Substances (SPS) Use and Hallucinogen Persisting Perception Disorder (HPPD): two case reports. J Psychiatry. 2014;51:277–280.
   Google Scholar
• Knuijver T, Belgers M, Markus W, et al. Hallucinogen persisting perception disorder after ibogaine treatment for opioid dependence. J Clin Psychopharmacol. 2018;38(6):646–648.
   PubMed Web of Science ®Google Scholar
• Young CR. Sertraline treatment of hallucinogen persisting perception disorder. J Clin Psychiatry. 1997;58(2):85.
   PubMed Web of Science ®Google Scholar
• Brodrick J, Mitchell BG. Hallucinogen Persisting Perception Disorder and Risk of Suicide. J Pharm Pract. 2016;29(4):431–434.
   PubMedGoogle Scholar
• Casa B, Bosio A. Levetiracetam efficacy in hallucinogen persisting perception disorders: a prospective study. J Neurol Sci. 1589;2005(238):S504.
   Google Scholar
• Batzer W, Ditzler T, Brown C. LSD use and flashbacks in alcoholic patients. J Addict Dis. 1999;18(2):57–63.
   PubMed Web of Science ®Google Scholar
• Martinotti G, Santacroce R, Pettorruso M, et al. Hallucinogen Persisting Perception Disorder: etiology, clinical features, and therapeutic perspectives. Brain Sci. 2018;8(3):47.
   Web of Science ®Google Scholar
• Green A, Mechan A, Elliott J, et al. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”). Pharmacol Rev. 2003;55(3).
   PubMed Web of Science ®Google Scholar
• De Gregorio D, Enns J, Nuñez N, et al. d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: mechanism of action and potential therapeutic applications in mood disorders. Prog Brain Res. 2018; 242.
   PubMed Web of Science ®Google Scholar
• Sigel E, Ernst M. The benzodiazepine binding sites of GABAA receptors. Trends Pharmacol Sci. 2018;39(7):659–671.
   PubMed Web of Science ®Google Scholar
• Pitman RK, Rasmusson AM, Koenen KC, et al. Biological Studies of Posttraumatic Stress Disorder. Nat Rev Neurosci. 2012;13(11):769.
   PubMed Web of Science ®Google Scholar
• Belkin MR, Schwartz TL. Alpha-2 receptor agonists for the treatment of posttraumatic stress disorder. Drugs Context. 2015;4.
   PubMedGoogle Scholar
• Lev-Ran S, Feingold D, Frenkel A, et al. Clinical characteristics of individuals with schizophrenia and hallucinogen persisting perception disorder: a preliminary investigation. Journal of Dual Diagnosis. 2014;10(2):79–83.
   PubMed Web of Science ®Google Scholar
• Leptourgos P, Fortier-Davy M, Carhart-Harris R, et al. Hallucinations Under Psychedelics and in the Schizophrenia Spectrum: An Interdisciplinary and Multiscale Comparison. Schizophrenia Bulletin. 2020;46(6):1396–1408.
   PubMed Web of Science ®Google Scholar
• Rattehalli RD, Jayaram MB, Smith M. Risperidone versus placebo for schizophrenia. Cochrane Database Syst Rev. 2010. CD006918. 10.1002/14651858.CD006918.
   Web of Science ®Google Scholar
• Rattehalli RD, Zhao S, Li BG, et al. Risperidone versus placebo for schizophrenia. Cochrane Database Syst Rev. 2016; 12. CD006918 10.1002/14651858.CD006918.pub3
   PubMedGoogle Scholar
• Halpern JH. Hallucinogen persisting perception disorder: what do we know after 50 years? Drug Alcohol Depend. 2003;69(2):109–119.
   PubMed Web of Science ®Google Scholar
• Strassman RJ. Adverse reactions to psychedelic drugs. A review of the literature. J Nerv Ment Dis. 1984;172(10):577–595.
   PubMed Web of Science ®Google Scholar